Lanean...
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003
PURPOSE: We hypothesized that bevacizumab will potentiate activity of pembrolizumab. We conducted a phase Ib/II, single-arm, multisite clinical trial of the combination in metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients with metastatic clear cell RCC who experienced progression...
Gorde:
| Argitaratua izan da: | J Clin Oncol |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society of Clinical Oncology
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7145584/ https://ncbi.nlm.nih.gov/pubmed/32097091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02394 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|